Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.0361 | 0.3511 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.0361 | 0.3511 | 0.9604 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0361 | 0.3511 | 0.9706 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.0217 | 0.1031 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0361 | 0.3511 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0367 | 0.3617 | 1 |
Echinococcus granulosus | biogenic amine 5HT receptor | 0.0405 | 0.427 | 0.1023 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.0217 | 0.1031 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0217 | 0.1031 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0367 | 0.3617 | 1 |
Giardia lamblia | Hypothetical protein | 0.0217 | 0.1031 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0217 | 0.1031 | 0.5 |
Echinococcus multilocularis | biogenic amine (5HT) receptor | 0.0405 | 0.427 | 0.1037 |
Schistosoma mansoni | biogenic amine (5HT) receptor | 0.0405 | 0.427 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0361 | 0.3511 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.0367 | 0.3617 | 1 |
Onchocerca volvulus | 0.0367 | 0.3617 | 0.5 | |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0367 | 0.3617 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0367 | 0.3617 | 1 |
Echinococcus multilocularis | conserved hypothetical protein | 0.0733 | 0.9913 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -7.646 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.